PFIZER

Pfizer share price & financials

Price
₹4,566.9
Market cap
₹18.6k Cr
Sector
Healthcare
Calls analysed
5
Latest concall · Q1 FY21 · call held 05 Aug 2020

Pfizer Q1 FY21

Revenue from Operations ₹515 cr −5%EBITDA Margin 37% PAT ₹124 cr +10%

Revenue from Operations ₹515 cr (−5% YoY); EBITDA Margin 37%; PAT ₹124 cr (+10% YoY). Revenue from operations stood at ₹515 crores, a decline of 5.3% YoY due to COVID-19 impact on hospital and vaccine segments.

Read the full call →

What Pfizer Limited does

Pfizer Limited is the India-listed subsidiary of global drugmaker Pfizer Inc., manufacturing and marketing branded prescription pharmaceuticals sold through hospitals, nursing homes and retail pharmacies. Its portfolio spans vaccines, hospital anti-infectives/critical care, internal medicine and women's healthcare, promoted to physicians via field sales teams and distribution partnerships (e.g. with GoApptiv and Mylan Pharmaceuticals). The company runs its own tablet manufacturing plant at Goa and reports as a single 'Pharmaceuticals' business segment under Ind AS.

Segments

  • Internal Medicine
  • Vaccines
  • Hospitals Business Unit (HBU)
  • Women's Healthcare
Manufacturing facility
Tablet manufacturing plant at Goa
Business divisions
Internal Medicine, Vaccines, Hospitals (anti-infectives) and Women's Healthcare
Healthcare professionals prescribing Internal Medicine brands
2.7 lakh+
Years operating in India
75 (since 1950)
Solar power installed capacity at Goa plant
1,500 kWp
Founded 1950Headquarters Mumbai, Maharashtra, India Company website

Guidance record · Q1 FY21

what the last two calls moved 10 tracked 6 delivered 4 missed 0 open
  • EBITDA Margin delivered said Q1 FY17 Promised: 21-22% Q1 FY21: Q1 FY21 margin was 37%. Management guided for a normalized 25-30% range, well above the original target.
  • Full Year Pricing Impact delivered said Q1 FY17 Promised: ₹80-90 crores Q1 FY21: The promise tracker in the Q1 FY21 data states this was 'not_addressed' in that specific call.

All 10 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 8.3%, net profit up 6.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue589 538 592 603 642 +9%645 +20%629 +6%653 +8%
EBITDA189 146 228 210 230 +22%228 +56%236 +4%248 +18%
Net profit158 128 331 192 189 +20%142 +11%200 −40%204 +6%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −21.0% 1Y

₹4.0k₹4.5k₹5.0k₹5.5kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹5,140.5 on 10 Sept 2025 → ₹4,060.2. High ₹5,529.5 (13 Oct 2025), low ₹4,060.2 (11 Sept 2026).

Financials, as filed

Revenue grew 1.3% a year over 3 years, FY23 to FY26. Operating margin widened to 35.9%.

Year endingFY23FY24FY25FY26
Revenue₹2.4k Cr₹2.2k Cr₹2.3k Cr₹2.5k Cr
Operating profit₹809 Cr₹636 Cr₹740 Cr₹904 Cr
Operating margin33.4%29.0%32.4%35.9%
Interest₹14 Cr₹16 Cr₹9 Cr₹9 Cr
Depreciation₹105 Cr₹63 Cr₹61 Cr₹57 Cr
Net profit₹625 Cr₹552 Cr₹768 Cr₹723 Cr
Net margin25.8%25.2%33.7%28.7%
Cash from operations₹356 Cr₹257 Cr₹660 Cr₹968 Cr
Free cash flow₹292 Cr₹291 Cr₹783 Cr₹944 Cr
ROCE26.0%22.0%21.0%24.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹46 Cr₹46 Cr₹46 Cr₹46 Cr₹46 Cr₹46 Cr
Reserves₹2.3k Cr₹2.8k Cr₹3.2k Cr₹3.5k Cr₹3.8k Cr₹4.2k Cr
Borrowings₹63 Cr₹39 Cr₹41 Cr₹40 Cr₹43 Cr₹70 Cr
Other liabilities₹810 Cr₹997 Cr₹752 Cr₹593 Cr₹714 Cr₹649 Cr
Total liabilities₹3.3k Cr₹3.9k Cr₹4.0k Cr₹4.2k Cr₹4.6k Cr₹4.9k Cr
Fixed assets₹894 Cr₹869 Cr₹749 Cr₹713 Cr₹701 Cr₹678 Cr
Capital work in progress₹3 Cr₹1 Cr₹8 Cr₹0 Cr₹8 Cr₹20 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹2.4k Cr₹3.0k Cr₹3.2k Cr₹3.5k Cr₹3.9k Cr₹4.2k Cr
Total assets₹3.3k Cr₹3.9k Cr₹4.0k Cr₹4.2k Cr₹4.6k Cr₹4.9k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −0.75 pp while DIIs added +0.57 pp.

Promoters
63.9%
FIIs
1.6%
DIIs
17.8%
Public
16.6%

Since Jun 2025

  • FIIs −0.75 pp
  • DIIs +0.57 pp
  • Public +0.17 pp

How it drifted, 12 quarters

Over this window DIIs went from 15.0% to 17.8% — +2.8 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 63.9%, FIIs 2.8%, DIIs 15.0%, Public 18.2%.Dec '23: Promoters 63.9%, FIIs 3.0%, DIIs 15.2%, Public 17.9%.Mar '24: Promoters 63.9%, FIIs 3.3%, DIIs 15.3%, Public 17.4%.Jun '24: Promoters 63.9%, FIIs 3.2%, DIIs 15.8%, Public 17.0%.Sep '24: Promoters 63.9%, FIIs 3.5%, DIIs 16.0%, Public 16.5%.Dec '24: Promoters 63.9%, FIIs 2.7%, DIIs 16.8%, Public 16.5%.Mar '25: Promoters 63.9%, FIIs 2.2%, DIIs 17.1%, Public 16.8%.Jun '25: Promoters 63.9%, FIIs 2.4%, DIIs 17.2%, Public 16.4%.Sep '25: Promoters 63.9%, FIIs 2.6%, DIIs 17.1%, Public 16.4%.Dec '25: Promoters 63.9%, FIIs 2.7%, DIIs 17.1%, Public 16.3%.Mar '26: Promoters 63.9%, FIIs 2.8%, DIIs 16.9%, Public 16.4%.Jun '26: Promoters 63.9%, FIIs 1.6%, DIIs 17.8%, Public 16.6%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Pfizer Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Pfizer East India B V 39.75%unchanged
Wyeth Llc 12.28%unchanged
Nippon Life India Trustee Ltd. Mutual fund4.17%unchanged
Life Insurance Corporation Of India Insurer3.74%−0.11 pp
Wyeth Holdings Corporation 3.56%unchanged
ICICI Prudential Fund Mutual fund3.31%+1.15 pp
Warner-Lambert Company Llc 2.60%unchanged
Quant Mutual Fund Mutual fund2.22%unchanged
Atul Limited 2.10%unchanged
Parke, Davis & Company Llc 2.09%unchanged
John Wyeth & Brother Ltd 1.93%unchanged
Pharmacia Corporation 1.71%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in PFIZER

Filings to Aug 2026

0 new, 4 added, 1 trimmed, 0 sold out — net +0.00 L shares (+0.0%).

Held by funds
₹899 Cr
8 schemes
Biggest holder
Nippon India Small Cap Fund
₹565 Cr · 0.7% of that fund
SchemeHoldingLast month
Nippon India Small Cap Fund Nippon India Mutual Fund₹565 Crheld
Nippon India Multi Cap Fund Nippon India Mutual Fund₹167 Crheld
Nippon India Pharma Fund Nippon India Mutual Fund₹149 Crheld
Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund₹11 Cr+0.00 L
SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund₹6 Cr+0.00 L
Nippon India Nifty 500 Equal Weight Index Fund Nippon India Mutual Fund₹1 Cr+0.00 L
SBI Nifty 500 Index Fund SBI Mutual Fund₹0 Cr−0.00 L
SBI Nifty Small Cap 250 ETF SBI Mutual Fund₹0 Cr+0.00 L

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

4 added, 1 trimmed — net +434 shares (+0.0%)

Funds are sitting on
+7%
vs est. average cost
Held by funds
₹899 Cr
8 schemes · ≈ 4.7% of the company
Biggest holder
Nippon India Small Cap Fund
₹565 Cr · 0.7% of that fund
Longest holder
Nippon India Pharma Fund
5y 4m · since May '21

Shares held by these funds +21%

Aug '23 19.20 L shares Jul '26

What the price assumes

Fair

To justify its price of ₹4060, this stock must grow earnings at 18% every year for 7 years. Our analysis caps realistic growth at ~17%. At that growth it is worth ₹3777 — downside of 7%.

Growth the price implies
18.1% a year
for 7 years, fading to 4%
It has actually compounded at
16.7% a year
net profit, FY23–FY26 · EPS 16.8%
The gap
0.0 pp
-7% downside if it only repeats history
Price today ₹4,060.2 Value at the reference growth ₹3,777.42

Change the assumptions yourself →

All earnings calls (5)

Read the Q1 FY21 call →

Learn to analyse Pfizer Limited

Guides on how to read this kind of business and the numbers that matter.